跳至主要内容
临床试验/NCT02872896
NCT02872896已完成不适用

The Role of Noninvasive Beat-to-Beat ClearSight Blood Pressure Monitoring During Non-cardiac Surgery

The Cleveland Clinic2 个研究点 分布在 1 个国家目标入组 320 人开始时间: 2016年10月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
320
试验地点
2
主要终点
Time- weighted average (TWA) MAP

研究概览

简要总结

Subjects will first have a blood pressure reading recorded on both arms using a non-invasive blood pressure monitoring (NIBP) cuff in the preoperative area. Then blood pressure will be recorded using the ClearSight monitor on each hand over a one-minute period. If mean arterial pressure (MAP) as assessed by either the noninvasive blood pressure (NIBP) monitoring cuff or the ClearSight system differs by more than 10% from arm to arm, the subject will be excluded from the study.

Before induction of anesthesia, the subject will be randomized to either:

ClearSight group + usual clinical care: Information from ClearSight monitor will be available to the clinicians. According to ASA guidelines, usual blood pressure monitoring includes non-invasive blood pressure measurements every 5 minutes during a surgical case.

Non-ClearSight group (blinded) + usual clinical care: Information from ClearSight monitor will not be available to the clinicians.

Both patient groups will have continuous ClearSight monitoring and non-invasive blood pressure monitoring every 5 minutes. The difference will be in the intervention group data from the monitor will be available to the clinicians in the operating room, but in the control group data from the ClearSight monitor will not be available (blinded) to the clinicians. Regardless of the study group assignment, second-by-second ClearSight monitor continuous blood pressure data will be recorded for each study patient and will be used for analysis.

The morning of post-operative day 3 the subject will be given the QoR-15 questionnaire and will complete POMS morbidity surveys.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
45 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Written informed consent
  • Age > 45 years
  • ASA Physical Status 3 or 4
  • Moderate- or high-risk non-cardiac surgical procedures (i.e., orthopedic, spine, urology, and general surgery) in patients in whom invasive blood pressure monitoring is not planned
  • Anticipated surgical duration >2 hours

排除标准

  • Any contraindications to the proposed interventions
  • Patient with invasive blood pressure monitoring
  • Patients with contraindications to oscillometric blood pressure monitoring on one arm and ClearSite monitoring on the other
  • Preoperative discrepancy in mean arterial pressure >10% between the arms

研究组 & 干预措施

ClearSight device

Experimental

Patients having orthopedic, urologic or general surgery will have blood pressure monitored by the ClearSight device second by second throughout surgery.

干预措施: Orthopedic, urologic or general surgery (Procedure)

Non-ClearSight

Sham Comparator

Patients having orthopedic, urologic or general surgery will have blood pressure monitored by the Non-ClearSight (the clinical team) every 5 minutes throughout surgery.

干预措施: Orthopedic, urologic or general surgery (Procedure)

结局指标

主要结局

Time- weighted average (TWA) MAP

时间窗: 2 hours

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kamal Maheshwari, MD MPH

Principal Investigator

The Cleveland Clinic

研究点 (2)

Loading locations...

相似试验